Cargando…
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
BACKGROUND: The objective of CaLIPSO, a Phase 2b, randomized, double-blind, placebo-controlled clinical trial, is to test the hypothesis that myo-inositol hexaphosphate (SNF472) attenuates the progression of cardiovascular calcification in patients receiving maintenance haemodialysis. Here we report...
Autores principales: | Bellasi, Antonio, Raggi, Paolo, Bover, Jordi, Bushinsky, David A, Chertow, Glenn M, Ketteler, Markus, Rodriguez, Mariano, Sinha, Smeeta, Salcedo, Carolina, Garg, Rekha, Gold, Alex, Perelló, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857813/ https://www.ncbi.nlm.nih.gov/pubmed/33564440 http://dx.doi.org/10.1093/ckj/sfz144 |
Ejemplares similares
-
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
por: Raggi, Paolo, et al.
Publicado: (2020) -
Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification
por: Ferrer, Miguel D., et al.
Publicado: (2018) -
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis
por: Sinha, Smeeta, et al.
Publicado: (2021) -
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels
por: Perelló, Joan, et al.
Publicado: (2018) -
Lateral Boundary of Cirrus Cloud from CALIPSO Observations
por: Fu, Yunfei, et al.
Publicado: (2017)